Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. The Advance Safety Needle System was tested in 2021 and is now being sold into accounts using Kurin.
“We are proud to commercialize the Advance Safety Needle, as there has been market demand for alternatives and improvements in this space,” said Bob Rogers, CEO of Kurin, Inc. “We are pleased with our field trials performed over the past several months. In addition to the positive feedback that we received, our testing shows improved performance characteristics compared to traditional, retraction-oriented products. The development of the Advance Needle is an important milestone for Kurin, providing us a more reliable supply of product, better cost control, the opportunity to offer improved benefits over current needles, and creates new strategic opportunities in which we are already engaged.”
Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.